摘要
目的探讨唑来磷酸联合卡培他滨治疗乳腺癌多发骨转移的效果及安全性。方法将48例乳腺癌骨转移患者随机分为唑来磷酸联合卡培他滨组(治疗组)及单用唑来磷酸组(对照组),分别对两组进行镇痛效果、生存质量改善评价、骨转移灶治疗效果评价及观察不良反应。结果两组患者治疗后骨痛的镇痛效果评价、患者生存质量改善评价,差异均无统计学意义(P>0.05);两组骨转移灶治疗效果评价,差异有统计学意义(P<0.05);两组患者的乏力、发热、恶心、呕吐、腹泻发生率比较,差异均无统计学意义(P>0.05)。结论唑来磷酸联合卡培他滨对乳腺癌骨多发转移较单用唑来磷酸有较好的治疗效果。
Objective To investigate the efficacy and safety of zoledronic acid combined with capecitabine in treating breast cancer patients with multiple bone metastases. Methods 48 breast cancer patients with multiple bone metastases were randomly divided into two groups： group zoledronic acid plus capecitabine （treatment group） and group zoledronic acid alone （ control group）. Analgesic effect, quality of life improvement, effect of the treatment for bone metastases and toxicity were com- pared between two groups. Results There was no significant difference in terms of analgesic effect and quality of life improve- ment between two groups （ P 〉 0. 05 ）. The response rate of bone metastases between two groups showed significant difference （ P〈0. 05）. In terms of anergy, fever, nausea, vomit and diarrhea, no significant difference between the two groups was found （P 〉 O. 05 ）. Conclusion Zoledronic acid combined with capecitabine in treating breast cancer patients with bone metastases shows a better efficacy than zoledronic acid.
出处
《中国全科医学》
CAS
CSCD
北大核心
2011年第35期4103-4105,共3页
Chinese General Practice
关键词
乳腺肿瘤
骨转移
唑来磷酸
卡培他滨
Breast neoplasms
Bone metastases
Zoledronic acid
Capecitabine
